3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
4
Hodgkin Disease
3
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Recurrence
2
Neoplasms
2
Advanced Breast Cancer
2
Neoplasm Metastasis
1
NSCLC
1
Metastatic HER2-positive Breast Cancer
1
Lung Neoplasms
1
HER2-positive Advanced Breast Cancer
1
HER2-negative Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Adenocarcinoma
1
Interventions
Drug Therapy
4
Pemetrexed
3
Carboplatin
3
osimertinib
2
Radiotherapy
2
toripalimab
1
tislelizumab
1
sugemalimab
1
spartalizumab
1
sintilimab
1
pembrolizumab
1
cemiplimab
1
aflutinib
1
Vinorelbine
1
Radiosurgery
1
Platinum
1
Paclitaxel
1
Gemcitabine
1
Docetaxel
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Anterior Temporal Lobectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
NSCLC
×
Vinorelbine
×
Clear all
NCT06576635
2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA
Recruiting
29 enrolled